Clinical Trials Directory

Trials / Completed

CompletedNCT01143025

Intraperitoneal Ropivacaine Nebulization for Pain Control After Laparoscopic Surgery

Peritoneal Nebulization of Ropivacaine for Postoperative Pain Control After Laparoscopic Cholecystectomy

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
165 (estimated)
Sponsor
San Gerardo Hospital · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess if intraperitoneal nebulization of Ropivacaine 50 mg, 100 mg or 150 mg may prevent the use of morphine during the first day after laparoscopic cholecystectomy.

Detailed description

Intraperitoneal aerosolization of Bupivacaine 50 mg after laparoscopic cholecystectomy has been proved to significantly reduce postoperative pain, morphine consumption and incidence of postoperative nausea and vomiting in comparison with patients receiving direct instillation of Bupivacaine 50 mg or placebo. Ropivacaine can be effectively administrated with non-heating nebulizers (AeronebPro®). In a recent study our group found that nebulization of Ropivacaine 30 mg with the AeronebPro® before or after laparoscopic cholecystectomy significantly reduced postoperative pain and morphine consumption. Nonetheless, most patients still need strong opioid based analgesia after surgery. We hypothesize that intraperitoneal nebulization of Ropivacaine 100 mg and 150 mg (maximum recommended dose in adults 300 mg or up to 3 mg/kg) may prevent the use of morphine during the first day after surgery maintaining ropivacaine plasma levels below toxic concentration.

Conditions

Interventions

TypeNameDescription
DRUGRopivacaine 50 mgPreoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
DRUGRopivacaine 100 mgPreoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
DRUGRopivacaine 150 mgPreoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity

Timeline

Start date
2010-03-01
Primary completion
2011-04-01
Completion
2011-05-01
First posted
2010-06-14
Last updated
2011-05-19

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT01143025. Inclusion in this directory is not an endorsement.